ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 8.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,574 shares of the specialty pharmaceutical company’s stock after selling 1,900 shares during the quarter. Los Angeles Capital Management LLC owned 0.09% of ANI Pharmaceuticals worth $1,082,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV lifted its holdings in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the period. HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $222,000. James Investment Research Inc. acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $243,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after buying an additional 412 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Buying and Selling

In related news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,300 shares of company stock valued at $584,009. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $61.89 on Friday. The firm has a market cap of $1.30 billion, a PE ratio of -112.53 and a beta of 0.74. The firm has a fifty day moving average of $57.23 and a 200 day moving average of $58.13. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.81.

Analyst Ratings Changes

A number of analysts have recently commented on ANIP shares. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.